BofA/Merrill Lynch Upgrades Idenix Pharmaceuticals Inc. (IDIX) to Buy
Tweet Send to a FriendGet Alerts IDIX Hot Sheet
Price: $4.31 +2.86%
Rating Summary:
5 Buy, 11 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
5 Buy, 11 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade IDIX Now!
BofA/Merrill Lynch upgraded Idenix Pharmaceuticals Inc. (NASDAQ: IDIX) from Neutral to Buy.
For more ratings news on Idenix Pharmaceuticals Inc. click here and for the rating history of Idenix Pharmaceuticals Inc. click here.
Shares of Idenix Pharmaceuticals Inc. closed at $2.90 yesterday, with a 52 week range of $2.57-$6.11.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
For more ratings news on Idenix Pharmaceuticals Inc. click here and for the rating history of Idenix Pharmaceuticals Inc. click here.
Shares of Idenix Pharmaceuticals Inc. closed at $2.90 yesterday, with a 52 week range of $2.57-$6.11.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: A.G. Lafley Gives Procter & Gamble (PG) Investors 'New Hope', UBS Upgrades to Buy
- First Analysis Upgrades Volcano Corp. (VOLC) to Overweight
- Goldman Sachs Upgrades Atwood Oceanics (ATW) to Buy, Sees 24% Upside
Create E-mail Alert Related Categories
Hot Upgrades, UpgradesRelated Entities
Merrill Lynch, Bank of America
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
